Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

In vitro characterization of polyorthoester microparticles containing bupivacaine.

Deng JS, Li L, Tian Y, Ginsburg E, Widman M, Myers A.

Pharm Dev Technol. 2003;8(1):31-8.

PMID:
12665195
2.

The development of an injection-molding process for a polyanhydride implant containing gentamicin sulfate.

Deng JS, Meisters M, Li L, Setesak J, Claycomb L, Tian Y, Stephens D, Widman M.

PDA J Pharm Sci Technol. 2002 Mar-Apr;56(2):65-77.

PMID:
11977406
3.

Health status of employed and unemployed methadone patients.

Widman M, Lidz V, DiGregorio GJ, Platt AK, Robison L, Platt JJ.

J Subst Abuse Treat. 2000 Apr;18(3):287-9. No abstract available.

PMID:
10742644
4.

Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection.

Dale O, Hynne H, Parivar K, Johansson E, Widman M.

Acta Anaesthesiol Scand. 1999 Apr;43(4):415-20.

PMID:
10225075
5.

High performance laser diode bars with aluminum-free active regions.

Jansen M, Bournes P, Corvini P, Fang F, Finander M, Hmelar M, Johnston T, Jordan C, Nabiev R, Nightingale J, Widman M, Asonen H, Aarik J, Salokatve A, Nappi J, Rakennus K.

Opt Express. 1999 Jan 4;4(1):3-11.

PMID:
19396250
6.

In situ mapping of community-level cellular response with catalytic microbiosensors.

Peteu SF, Widman MT, Worden RM.

Biosens Bioelectron. 1998 Nov 15;13(11):1197-203.

PMID:
9871975
7.

In situ mutagenesis and chemotactic selection of microorganisms in a diffusion gradient chamber.

Mikola MR, Widman MT, Worden RM.

Appl Biochem Biotechnol. 1998 Spring;70-72:905-18.

PMID:
9627402
8.

A positron emission tomography study of cerebral blood flow and oxygen metabolism in healthy male volunteers anaesthetized with eltanolone.

Wessén A, Widman M, Andersson J, Hartvig P, Valind S, Hetta J, Långström B.

Acta Anaesthesiol Scand. 1997 Oct;41(9):1204-12.

PMID:
9366945
9.

Modeling microbial chemotaxis in a diffusion gradient chamber.

Widman MT, Emerson D, Chiu CC, Worden RM.

Biotechnol Bioeng. 1997 Jul 5;55(1):191-205.

PMID:
18636457
10.

Patterns of service use and treatment involvement of methadone maintenance patients.

Widman M, Platt JJ, Lidz V, Mathis DA, Metzger DS.

J Subst Abuse Treat. 1997 Jan-Feb;14(1):29-35.

PMID:
9218234
11.

Pharmacokinetics of eltanolone following bolus injection and constant rate infusion.

Parivar K, Wessén A, Widman M, Nilsson A.

J Pharmacokinet Biopharm. 1996 Dec;24(6):535-49.

PMID:
9300349
12.

Metabolism and excretion of ropivacaine in humans.

Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M.

Drug Metab Dispos. 1996 Sep;24(9):962-8.

PMID:
8886605
13.

Concentration-effect relationships of eltanolone given as a bolus dose or constant rate intravenous infusion to healthy male volunteers.

Wessén A, Parivar K, Widman M, Nilsson A, Hartvig P.

Anesthesiology. 1996 Jun;84(6):1317-26.

PMID:
8669672
14.

Uniform standards for substance user treatment research: an example from Germany for the United States and other countries.

Platt JJ, Bühringer G, Widman M, Künzel J, Lidz V.

Subst Use Misuse. 1996 Mar;31(4):479-92.

PMID:
8851813
15.

Barriers to out-of-hospital care for AIDS patients.

Widman M, Light DW, Platt JJ.

AIDS Care. 1994;6(1):59-67.

PMID:
8186279
16.

Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat.

Ogren SO, Hall H, Widman M, Angeby-Möller K.

Pharmacol Toxicol. 1993 Dec;73(6):325-34.

PMID:
8153056
17.

Disposition of remoxipride in different species. Species differences in metabolism.

Widman M, Nilsson LB, Bryske B, Lundström J.

Arzneimittelforschung. 1993 Mar;43(3):287-97.

PMID:
8489555
18.

Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat.

Ogren SO, Lundström J, Nilsson LB, Widman M.

J Neural Transm Gen Sect. 1993;93(3):187-203.

PMID:
8217058
19.

Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.

Köhler C, Radesäter AC, Karlsson-Boethius G, Bryske B, Widman M.

J Neural Transm Gen Sect. 1992;87(1):49-62.

PMID:
1531593
20.

Clinical pharmacokinetics of remoxipride.

von Bahr C, Movin G, Yisak WA, Jostell KG, Widman M.

Acta Psychiatr Scand Suppl. 1990;358:41-4. Review.

PMID:
1978486
21.

Synthesis of 5-substituted 5-hydroxy-2-pyrrolidones, metabolites of the antipsychotic benzamide remoxipride.

Gawell L, Hagberg CE, Högberg T, Widman M.

Acta Chem Scand. 1989 May;43(5):476-80.

PMID:
2577294
22.

The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males.

Farde L, von Bahr C, Wahlen A, Nilsson L, Widman M.

Int Clin Psychopharmacol. 1989 Apr;4(2):115-26.

PMID:
2526172
23.

Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.

Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L.

Pharmacol Rev. 1986 Mar;38(1):21-43. Review. No abstract available.

PMID:
3012605
24.

Cholinergic agents: antinociception without morphine type dependence in rats.

Widman M, Tucker S, Brase DA, Dewey WL.

Life Sci. 1985 May 27;36(21):2007-15.

PMID:
4039782
25.

A comparison between the metabolism of delta 1-tetrahydrocannabinol by perfused lung and liver of rat and guinea-pig.

Halldin MM, Isaac H, Widman M, Nilsson E, Ryrfeldt A.

Xenobiotica. 1984 Mar;14(3):277-82.

PMID:
6324501
26.

Glucuronic acid conjugate of delta 1-tetrahydrocannabinol identified in the urine of man.

Halldin MM, Widman M.

Arzneimittelforschung. 1983;33(1):177-8.

PMID:
6299309
27.

Identification of in vitro metabolites of delta 1-tetrahydrocannabinol formed by human livers.

Halldin MM, Widman M, V Bahr C, Lindgren JE, Martin BR.

Drug Metab Dispos. 1982 Jul-Aug;10(4):297-301.

PMID:
6126323
28.

Further urinary metabolites of delta 1-tetrahydrocannabinol in man.

Halldin MM, Andersson LK, Widman M, Hollister LE.

Arzneimittelforschung. 1982;32(9):1135-8.

PMID:
6293515
29.

Urinary metabolites of delta 1-tetrahydrocannabinol in man.

Halldin MM, Carlsson S, Kanter SL, Widman M, Agurell S.

Arzneimittelforschung. 1982;32(7):764-8.

PMID:
6289845
30.

Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse.

Ohlsson A, Widman M, Carlsson S, Ryman T, Strid C.

Acta Pharmacol Toxicol (Copenh). 1980 Oct;47(4):308-17.

PMID:
6258385
31.
32.

The importance of side-chain hydroxylated metabolites of delta6-tetrahydrocannabinol in rhesus monkey.

Halldin M, Widman M, Martin B.

Acta Pharm Suec. 1979;16(1):34-40. No abstract available.

PMID:
110031
33.

Acidic in vivo metabolites of cannabinol isolated from rat faeces.

Yisak AW, Widman M, Agurell S.

J Pharm Pharmacol. 1978 Sep;30(9):554-7.

PMID:
29093
34.

In vitro metabolism of tetrahydrocannabinol by rhesus monkey liver and human liver.

Widman M, Halldin M, Martin B.

Adv Biosci. 1978 Jul 22-23;22-23:101-3. No abstract available.

PMID:
116879
35.

In vivo metabolites of cannabinol identified as fatty acid conjugates.

Yisak W, Agurell S, Lindgren JE, Widman M.

J Pharm Pharmacol. 1978 Jul;30(7):462-3. No abstract available.

PMID:
27621
36.

Effects of divalent cations, lanthanum, cation chelators and an ionophore on acetylcholine antinociception.

Widman M, Rosin D, Dewey WL.

J Pharmacol Exp Ther. 1978 May;205(2):311-8.

PMID:
347052
37.

Neutral in vivo metabolites of cannabinol isolated from rat faeces.

Yisak WA, Widman M, Lindgren JE, Agurell S.

J Pharm Pharmacol. 1977 Aug;29(8):487-90.

PMID:
19598
38.

In vivo neutral metabolites of cannabinol from rat faeces [proceedings].

Yisak WA, Widman M, Agurell S, Lindren JE.

West Afr J Pharmacol Drug Res. 1977 Jun;4(1):83P-84P. No abstract available.

PMID:
602206
39.

In vivo neutral metabolites of cannabinol from rat faeces [proceedings].

Yisak WA, Widman M, Agurell S, Lindgren JE.

West Afr J Pharmacol Drug Res. 1977 Jun;4(1):61P. No abstract available.

PMID:
602189
40.

Dihydroxylated metabolites of cannabinol formed by rat liver in vitro.

Fonseka K, Widman M.

J Pharm Pharmacol. 1977 Jan;29(1):12-4.

PMID:
13175
41.

[Chemistry and metabolism of cannabinoids].

Widman M.

Lakartidningen. 1976 Nov 3;73(45):3857-9. Swedish. No abstract available.

PMID:
979450
42.

Chromatographic separation of cannabinoids and their monooxygenated derivatives.

Fonseka K, Widman M.

J Chromatogr. 1976 May 26;120(2):334-8.

PMID:
1270554
43.

Metabolism of delta1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism.

Widman M, Nordqvist M, Dollery CT, Briant RH.

J Pharm Pharmacol. 1975 Nov;27(11):842-8.

PMID:
1493
44.

In vitro metabolism of cannabinol in rat and rabbit liver. Syntheses of 2"-, 3"- and 5"-hydroxycannabinol.

Widman M, Dahmén J, Leander K, Petersson K.

Acta Pharm Suec. 1975;12(4):385-92. No abstract available.

PMID:
1199738
45.

Binding of (+)- and (minus)-delta-1-tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man.

Widman M, Agurell S, Ehrnebo M, Jones G.

J Pharm Pharmacol. 1974 Nov;26(11):914-6. No abstract available.

PMID:
4156569
46.

Monohydroxylated metabolites of delta-1-tetrahydrocannabinol in mouse brain. Comparison with in vitro liver metabolites.

Jones G, Widman M, Agurell S, Lindgren JE.

Acta Pharm Suec. 1974 Jun;11(3):283-94. No abstract available.

PMID:
4839738
47.

Biliary excretion of delta1-tetrahydrocannabinol and its metabolites in the rat.

Widman M, Nordqvist M, Agurell S, Lindgren JE, Sandberg F.

Biochem Pharmacol. 1974 Apr 1;23(7):1163-72. No abstract available.

PMID:
4823449
48.

Relative pharmacological potency in mice of optical isomers of delta 1-tetrahydrocannabinol.

Jones G, Pertwee RG, Gill EW, Paton WD, Nilsson IM, Widman M, Agurell S.

Biochem Pharmacol. 1974 Jan 15;23(2):439-46. No abstract available.

PMID:
4813356
49.

Two cannabidiol metabolites formed by rat liver.

Nilsson I, Agurell S, Nilsson JL, Widman M, Leander K.

J Pharm Pharmacol. 1973 Jun;25(6):486-7. No abstract available.

PMID:
4146589
50.

Plasma protein binding of 7-hydroxy- 1-tetrahydrocannabinol: an active 1-tetrahydrocannabinol metabolite.

Widman M, Nilsson IM, Agurell S, Borg H, Granstrand B.

J Pharm Pharmacol. 1973 Jun;25(6):453-7. No abstract available.

PMID:
4146583

Supplemental Content

Loading ...
Support Center